Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

1. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma.Frontiers in immunology · 2024
   Article
2. Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma.JCI insight · 2023
   Article
3. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022
   Article
4. Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma.Journal of nanobiotechnology · 2021
   Article
5. Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
   Article
6. Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
   Review
7. Validation of the International Prognostic Index and Subsequent Revisions for Diffuse Large B-Cell Lymphoma in Patients From the Middle East and North Africa Region.Cureus · 2020
   Article

Corrections and comments

• Comment on
  Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.2019

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as